Emerging strategies, such as nanoparticle-mediated delivery of STING and TLR4 agonists combined with RAS-targeted therapies, aim to remodel the immunosuppressive TME and activate durable anti-tumor immune responses [136]. This evidence concerns the gene STING1 and neoplasm.